News

Bharti Airtel Q4 Results

ASK Automotive Q4 Result

Bharti Hexacom Q4 Results

Quarter-on Quarter

GlaxoSmithKline Pharmaceuticals Q4 Results

Board Recommends Final Dividend of ₹42/Share

Aditya Birla Capital Q4 Results 

Jaguar Land Rover (JLR) Q4 Earnings

Tata Motors Q4 Results

Siemens Q2 Results

GAIL Q4  Results

Quarter-on-Quarter

Leading two-wheeler manufacturer Hero MotoCorp on Tuesday, May 13, reported its March quarter earnings slightly better than estimates. Price hike boosted margin and realisation.

Net profit for the quarter rose 6.4% from the year-ago period to ₹1,081 crore. A CNBC-TV18 poll had pegged the figure at ₹1,089 crore.

here

Earnings slightly better than estimates

Price hike boosts margin & realization

Q4FY25 (YoY)

Net Profit At `1,081 Cr Vs CNBC-TV18 Poll Of `1,089 Cr

Revenue At `9,939 Cr Vs CNBC-TV18 Poll Of `9,705 Cr

EBITDA At `1,417 Cr Vs CNBC-TV18 Poll Of `1,362 Cr

Margin At 14.26% Vs CNBC-TV18 Poll Of 14%

Net Profit up 6.4% At `1,081 Cr Vs `1,016 Cr (YoY)

Revenue up 4.4% At `9,939 Cr Vs `9,519 Cr (YoY)

EBITDA up 4.4% At `1,417.7 Cr Vs `1,359 Cr (YoY)

Margin At 14.3% Vs 14.30% (YoY)

Remain Cautiously Optimistic About The Near-To-Mid Term Outlook

Volumes down 1% YoY & down 6% QoQ

Volumes at 13.80 lk units Vs 13.92 lk units (YoY ) & Vs 14.63 lk units (QoQ)

Realisation up 5% YoY Vs estimate of 3% increase

Realisation up 3% QoQ Vs expectation of flat

WATCH OUT FOR

Inventory & discounting trend

Demand outlook and timeline of new launches

 #4QWithCNBCTV18 | Gail reports its Q4 earnings

Net Profit at ₹2,049 Cr Vs CNBC-TV18 Poll of ₹2,153 Cr pic.twitter.com/xAjiX1xKtK

— CNBC-TV18 (@CNBCTV18Live) May 13, 2025

Net Profit at ₹74 Cr Vs ₹29 Cr (YoY)

Revenue Down 2.2% at ₹1,051 Cr Vs ₹1,074.4 Cr (YoY)

EBITDA Up 59.60% at ₹146.40 Cr Vs ₹91.72 Cr (YoY)

Margin at 13.93% Vs 8.54% (YoY)#4QWithCNBCTV18 | Hero MotoCorp reports its Q4 earnings

Net Profit at ₹1,081 Cr Vs CNBC-TV18 Poll of ₹1,089 Cr pic.twitter.com/adhuM3k6Rc

— CNBC-TV18 (@CNBCTV18Live) May 13, 2025

–Net Profit Up 70% At ₹33.3 Cr Vs ₹19.6 Cr (YoY)

–Revenue Up 7% At ₹131.4 Cr Vs ₹122.8 Cr (YoY)

–EBITDA Up 65% At ₹44.4 Cr Vs ₹26.9 Cr (YoY)

–Margin At 33.79% Vs 21.91% (YoY)

– Net Profit Down 73% At ₹38 Cr Vs ₹140 Cr (YoY)

– Revenue Up 20% At ₹1,611.8 Cr Vs ₹1,343 Cr (YoY)

– EBITDA Down 8% At ₹218.3 Cr Vs ₹237.30 Cr (YoY)

– Margin At 13.5% Vs 17.7% (YoY)

– Cipla’s net profit at ₹1,214 crore, compared to a CNBC-TV18 poll of ₹1,052 crore

– Revenue up 9.2% from last year at ₹6,729 crore, in-line with estimates of ₹6,700 crore

– EBITDA up 16.8% to ₹1,537 crore but below expectations of ₹1,582 crore

– EBITDA margin at 22.84%, below the 24% expectation but higher by 184 bps from last year

– Cipla will also pay ₹16 per share as dividend

– Cipla reported a 16% jump in its other income, which contributed to its profitability, along with a lower tax outgo

– Net Profit Up 18% at ₹13.1 Cr Vs ₹11.1 Cr (YoY)

– Revenue Up 16% at ₹86 Cr Vs ₹74.3 Cr (YoY)

– EBITDA Loss at ₹1.5 Cr Vs EBITDA Of ₹0.5 Cr (YoY)

– To issue warrants to Promoters & Non-promoters at ₹134/Warrant

– To Issue warrants to Non-promoters incl Quant MF, Tejas Trivedi, Abakkus & Prashant Jain

Shares of agrochemicals major UPL Ltd declined over 5% on Tuesday, May 13, as brokerages remained divided on the stock. Read here

Outlook for Q1FY26

– Prices have moved up across geographics

– Europe EBITDA will move into the green

FY26

– Capex at ₹15k cr, Net Debt will be lower vs FY25

– UK turns EBITDA positive

– Net Profit Down 6.71% At ₹26.40 Cr Vs ₹28.30 Cr (YoY)

– Revenue Up 5.80% At ₹167 Cr Vs ₹158 Cr (YoY)

– EBITDA Down 18% At ₹45.50 Cr Vs ₹55.50 Cr (YoY)

– Margin At 27.23% Vs 35.13% (YoY)

– From Q1FY26, Europe will be EBITDA positive

– UK is heading towards breakeven on EBITDA in a couple of quarters

For its subsidiary Jaguar Land Rover (JLR), its net profit may increase by 19% from last year, while revenue may only see a modest 2% growth from last year. Its EBITDA may decline by 5%, while EBITDA margin may narrow by 90 basis points from last year, as per the CNBC-TV18 poll.

– Domestic sales expected to see a 9-11% growth

– Growth in domestic business to be led by base business and Sanofi’s CNS portfolio

– US sales estimate to be around $218 million – could decline around 3-4% QoQ

– US likely to declined due to lower sales of Lanreotide impacted by supply challenges

– Revlimid generic sales likely to be flattish – Estimate around $54 million vs $55 million QoQ

– One Africa estimated to grow over 15% YoY, and 8 to 9% growth in Europe + RoW

– EBITDA Margins estimate at around 23-24%

– APE seen up 6% at ₹3,038 cr vs ₹2,870 cr (YoY)

– Value of New Business (VNB) may fall 4% to ₹792 cr vs ₹820 cr

– VNB margin seen at 26.1% vs 28.6% (YoY)NewsLive TVMarketPopular CategoriesCalculatorsTrending NowLet's Connect with CNBCTV 18Network 18 Group :©TV18 Broadcast Limited. All rights reserved.